The potential of endothelin antagonism as a therapeutic approach

被引：12

作者：

Benigni, A ^{[1
]}

Perico, N ^{[1
]}

Remuzzi, G ^{[1
]}

机构：

[1] Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2004年 / 13卷 / 11期

关键词：

endothelin; endothelin-converting enzyme inhibitor; endothelin receptor antagonist;

D O I：

10.1517/13543784.13.11.1419

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutical companies that have set up high-throughput screens to search for antagonists of ET receptors. The emerging compounds have been tested in animals with exciting results, leading to great hope that such inhibitors could be translated into human drugs with desirable therapeutic activities and few side effects. This review will describe the most relevant results obtained in experimental animals in a wide variety of disease conditions and focus on the data of selected compounds that have been employed in clinical trials.

引用

页码：1419 / 1435

页数：17

共 176 条

[1]

ACHMAD TH, 1992, BIOCHEM BIOPH RES CO, V189, P994

[2] Endothelial-derived vasoactive mediators in polycystic kidney disease [J].

Al-Nimri, MA ;

Komers, R ;

Oyama, TT ;

Subramanya, AR ;

Lindsley, JN ;

Anderson, S .

KIDNEY INTERNATIONAL, 2003, 63 (05) :1776-1784

[3] Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].

Anand, I ;

McMurray, J ;

Cohn, JN ;

Konstam, MA ;

Notter, T ;

Quitzau, K ;

Ruschitzka, F ;

Lüscher, TF .

LANCET, 2004, 364 (9431) :347-354

[4] CLONING AND EXPRESSION OF A CDNA-ENCODING AN ENDOTHELIN RECEPTOR [J].

ARAI, H ;

HORI, S ;

ARAMORI, I ;

OHKUBO, H ;

NAKANISHI, S .

NATURE, 1990, 348 (6303) :730-732

[5]

ARAMORI I, 1993, MOL PHARMACOL, V43, P127

[6] Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].

Barst, RJ ;

Ivy, D ;

Dingemanse, J ;

Widlitz, A ;

Schmitt, K ;

Doran, A ;

Bingaman, D ;

Nguyen, N ;

Gaitonde, M ;

van Giersbergen, PLM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382

[7] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[8] Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation [J].

Barton, M ;

Shaw, S ;

dUscio, LV ;

Moreau, P ;

Luscher, TF .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238 (03) :861-865

[9] Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice [J].

Barton, M ;

Haudenschild, CC ;

D'Uscio, LV ;

Shaw, S ;

Münter, K ;

Lüscher, TF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14367-14372

[10] Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney [J].

Benigni, A ;

Zoja, C ;

Corna, D ;

Orisio, S ;

Facchinetti, D ;

Benatti, L ;

Remuzzi, G .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :416-423

← 1 2 3 4 5 6 7 8 9 10 →